USCareCheck

CMS certification 363302

Rainbow Babies and Childrens Hospital

11100 Euclid Avenue, Cleveland, OH 44106

Childrens

This page brings together federal quality data for this hospital: its CMS star rating, patient survey results, emergency department times, and death, complication, infection and readmission rates, each compared with the national rate. Everything here comes from CMS and NPPES, the federal sources themselves - not from us.

CMS overall rating Not rated Data are shown only for hospitals that participate in the Inpatient Quality Reporting (IQR) and Outpatient Quality Reporting (OQR) programs.
Would definitely recommend No survey results published
Patient survey rating Not rated HCAHPS patient survey
Compared with the nation Too few cases for CMS to compare

What patients said

Answers from patients who stayed here, collected by CMS in the national HCAHPS survey: Oct 2024 – Sep 2025.

Data are shown only for hospitals that participate in the Inpatient Quality Reporting (IQR) and Outpatient Quality Reporting (OQR) programs.

Not reported for this hospital

CMS had too few cases here to publish results for deaths, complications, infections caught in the hospital, readmissions and return visits. That is common at small, rural and specialty hospitals, and says nothing either way about quality.

Clinicians registered at this address

2,447 clinicians give this hospital's street address as their practice location in NPPES, the federal provider registry, plus 1,058 residents and trainees. The same address can take in offices and clinics in the building, and a listing does not prove admitting privileges or current employment.

Specialty Clinicians
Pediatrics 150
Internal Medicine 112
Anesthesiology 101
Physician Assistant 84
Acute Care 78
Anesthesiologist Assistant 73
Family 73
Diagnostic Radiology 72
Emergency Medicine 69
Nurse Practitioner 69
Pharmacist 58
Nurse Anesthetist, Certified Registered 57

First 12 alphabetically

Money from drug and device companies

Drug and device makers have to report what they pay teaching hospitals to CMS's Open Payments program. At many teaching hospitals most of it is research funding, or royalties for inventions the hospital licensed to a company. A payment on its own does not show a conflict of interest.

2025 total $3M general $258,105 · research $2.7M
All years, 2019–2025 $34.4M 4,480 reported payments
Studies funded, 2025 47 23 companies paid in total
  • 2019 $6.5M
  • 2020 $8.2M
  • 2021 $3.9M
  • 2022 $2.7M
  • 2023 $5.1M
  • 2024 $5.1M
  • 2025 $3M

General payments Research payments

What the 2025 general payments were for

Type of payment Amount Payments
Space rental and facility fees $204,605 16
Grants $23,000 5
Education $17,500 1
Gifts $7,500 1
Charitable contributions $5,500 1

Largest paying companies, 2025

Company Amount Payments
Regeneron Pharmaceuticals, Inc. $1.3M 590
Exelixis Inc. $550,929 119
Abbvie INC. $309,462 133
Medtronic, Inc. $165,105 7
Genentech, Inc. $154,036 29
Insulet Corporation $76,290 5
Y-mAbs Therapeutics, Inc. $64,666 14
Genmab U.S., Inc. $50,839 5

Largest research studies funded here, 2025

Study Amount
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK … Regeneron Pharmaceuticals, Inc. · NCT05608291 $483,522
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Ad… Exelixis Inc. $317,016
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVA… Regeneron Pharmaceuticals, Inc. · NCT05352672 $282,944
A Phase 2 and Phase 3 Peri-operative Trial of Fianlimab and Cemiplimab Compared With Anti-PD1 Alone in Patients With Resectable Stage III and IV Mela… Regeneron Pharmaceuticals, Inc. · NCT06190951 $278,546
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VE… Regeneron Pharmaceuticals, Inc. · NCT06091254 $241,845
A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-706 as Monotherapy and in Combination with Budigalimab (ABBV-… ABBVIE INC. · NCT05599984 $203,131
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors Exelixis Inc. $149,349
Safety and Efficacy of the Omnipod 5 SmartAdjust 2.0 System Compared to the Omnipod 5 System in Individuals with Type 1 or Type 2 Diabetes Insulet Corporation $76,290

Amounts are as the paying companies reported them to CMS; Open Payments data retrieved 13 Sep 2026. Full record on CMS Open Payments.

How to read this page

  • Everything here is published by CMS on Care Compare. We arrange it and explain it; the star ratings and the better / worse verdicts are CMS's, not ours.
  • “No different” is the most common result on most measures at most hospitals. CMS only calls a result better or worse when the difference from the national rate is statistically clear.
  • Death, complication and readmission rates are adjusted by CMS for how sick patients were, so hospitals that treat sicker patients can be compared fairly.
  • Infection results are ratios: 1.0 means as many infections as CMS predicted for a hospital like this one, below 1.0 is fewer.
  • These are hospital-wide results. They do not rate an individual doctor, nurse or department, and they are not medical advice.

CMS Care Compare data retrieved 4 Oct 2026, refreshed weekly. Where this data comes from and how we handle it · Report an error

Common questions about Rainbow Babies and Childrens Hospital

Does Rainbow Babies and Childrens Hospital have an emergency room?

No. CMS does not list emergency services at Rainbow Babies and Childrens Hospital.

Does Rainbow Babies and Childrens Hospital receive money from drug and device companies?

Drug and device makers reported $3M in payments to Rainbow Babies and Childrens Hospital for 2025, most of it research funding, under the federal Open Payments program. A payment on its own does not show a conflict of interest.